Join Now | Print Page | Contact Us | Sign In
Private Equity Group Meeting - "Demystifying The Private Equity Operating Partner Role"
View Registrations Tell a Friend About This EventTell a Friend

This meeting is open to ALL GPSEG MEMBERS. Crowne Plaza - KOP Members - $35

When: Tuesday, February 16, 2016
12:00PM - 2:30PM
Where: Crowne Plaza - KOP
260 Mall Boulevard
King of Prussia, Pennsylvania  19406
United States
Presenter: Paul Litwack - CEO, Axcentria Pharmaceuticals
Contact: Maureen Waddington

Online registration is closed.
« Go to Upcoming Event List  

Meeting Open to ALL GPSEG Members!

Registration - $35


Private Equity Group Meeting


Tuesday, February 16, 2016

12:00 - 2:30pm 


Crowne Plaza

260 Mall Boulevard

King of Prussia, Pa  19406



Demystifying The Private Equity Operating Partner Role



Paul Litwack

CEO, Axcentria Pharmaceuticals



The Operating Partner plays a crucial role for many private equity firms and their portfolio companies. Unlike fund general or limited partners or portfolio company leaders, the OP bridges two very different worlds, often having to “pray to two Gods.”  Typically a highly stimulating and challenging role, it remains difficult for executives to land these somewhat scarce positions, especially if you are not a widely known senior executive.


Paul Litwack, currently CEO of PE-sponsored Axcentria Pharmaceuticals, has held the OP role numerous times for different private equity firms, working closely with a wide variety of management teams – electrical components, basic materials, food and pharmaceuticals. He will discuss how to best position yourself for the role, truths and myths, and offer guidance on sizing up opportunities.


About Paul Litwack



Paul Litwack is currently CEO of Axcentria Pharmaceuticals. He is a proven business builder with 20-plus years of experience as CEO of several middle-market corporations – DA-Tech, Protective Armored Systems and Frankford Candy among others. His business-to-business industrial products experience is complemented by his consumer packaged goods and brand-building expertise, acquired at General Mills, RJR Nabisco and Kraft Foods. Paul’s strengths include strategic planning, business development, M&A and marketing and sales management.  Paul earned an MBA from the University of Pennsylvania’s Wharton School of Business and a B.S. from Brown University.  He currently serves as a director on the boards of several private, middle market companies.


About Axcentria Pharmaceuticals



Axcentria Pharmaceuticals was formed in 2010 by executives and investors, all with experience in the prescription drug and dental products industries. The company is a premier private label manufacturer of specialty liquids, creams and ointments serving the pharmaceutical, dental and veterinary products industries. In 2014, Axcentria expanded its focus on the $3.5 billion and rapidly growing e-cigarette and vaping markets. Today, Axcentria serves as a trusted “virtual” partner for product development, procurement, manufacturing, product testing, warehousing, inventory management and customer fulfillment for many OTC and Rx product companies.


Much more about Paul and Axcentria at


Save the Date


March 15 - Carl Rapp, President & CEO of Philadelphia Gear, and Vice President, Timken, will offer an insider's perspective on the very different challenges and operating environments senior executives must navigate in private equity versus publicly traded companies.

April 19 - Paul Halpern, Chief Investment Officer of Versa Capital Management, a large, successful Philly-based private equity firm focused on investing in distressed companies, will address the group on "Finding Diamonds in the Rough."